Abstract
Obesity is one of the leading problems in our society. The spread of obesity in developed societies is reaching pandemic lengths. In schizophrenic patients obesity raises an important issue. Patients suffering from schizophrenia have a shorter life span compared to the general population. Prevalence of obesity in schizophrenic patients is high. Obesity is the key factor in developing a metabolic syndrome. Metabolic syndrome is a frequent somatic complication in schizophrenia. Nowadays, it is clear that metabolic syndrome shortens the lifespan of people who developed an illness. Because of this, the treatment of obesity represents a major problem. Review of currently approved medications for treatment of obesity is the goal of this paper.
Publisher
Centre for Evaluation in Education and Science (CEON/CEES)
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference82 articles.
1. Schneider-Thoma J, Efthimiou O., Huhn M. et al. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry 2018;5:653-63;
2. Jeste DV., Gladsjo JA., Lindamer LA. et al. Medical comorbidity in schizophrenia. Schizophrenia Bull 1996; 22: 413-430;
3. Sims AC. Mortality statistics in psychiatry. Br J Psychiatry 2001; 179:477-8;
4. Grundy SM., Brewer HB., Cleeman JI. et al. Definition of metabolic syndrome: report of the National Heart, Lung and Blood Institute/ American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004;109:433-8;
5. American Heart Association: Heart diseasse and stroke statistics: 2006 update. Circulation, January 11, 2006 (epub), Avilable at: http://circ.ahajournals.org/cgi/content/full/113/6/e85;